 |
|
31.08.2010 Health Canada Grants Full
Approval of Sativex For the Treatment of Spasticity
Due to Multiple Sclerosis |
|
GW Pharmaceuticals
(AIM: GWP)
and Bayer Inc.,
a subsidiary of Bayer AG,
today announced that Health Canada has approved Sativex®
[delta-9-tetrahydrocannabinol 27 mg/mL (from Tetrabinex®
- cannabis sativa L. extract) and cannabidiol 25 mg/mL
(from Nabidiolex® - cannabis sativa L. extract)] as
adjunctive treatment for symptomatic relief of
spasticity in adult patients with multiple sclerosis
(MS). Sativex® is the first cannabinoid medicine derived
from whole plant extracts from the cannabis sativa plant
containing both delta-9-tetrahydrocannabinol and
cannabidiol. This means that people in Canada with MS
experiencing the debilitating symptoms of spasticity,
such as painful spasms and cramps, will now have a new
treatment option in addition to standard therapy.
 |
 |
|
|
|
 |
|
|
31.08.2010 Vetter Opens New Sales
Office at Illinois Science + Technology Park in Suburban
Chicago |
|
In keeping with its
strategy of U.S. growth and expansion, Vetter, a
specialist in aseptically prefilled drug-delivery
systems, today announced that it has opened a new sales
office at the Illinois Science +Technology Park in
Skokie. The office will be managed by Mr. Troy
Carpenter, who was appointed as President of Vetter
Pharma International USA Inc. The new office replaces
its Yardley, Pennsylvania sales office, founded in 1983
as Vetter Pharma-Turm Inc. The establishment of the new
office in the Midwest region, considered an emerging
“hotspot” in biotechnology, is consistent with the
company’s stated objective for worldwide growth by
focusing on the emerging pharmaceutical and
biotechnology market in North America. The office, to be
officially known as Vetter Pharma International USA
Inc., is a wholly owned subsidiary of
Vetter
Pharma
International GmbH, which is responsible for Vetter’s
sales and marketing as well as customer service
functions. In 2009, Vetter announced the creation of its
first U.S. manufacturing facility, also located at the
Illinois Science + Technology Park. The facility – an
expansion of Vetter Development Service – is scheduled
to be operational in the beginning of the fourth quarter
of 2010.
|
 |
|
|
|
 |
|
|
25.08.2010 Brookwood International
Academy And Argint International Announce Strategic Partnership |
|
Argint International
(“Argint”), a clinical research organisation
based in Central and South-Eastern Europe, and Brookwood
International Academy (“the Academy”), an independent academy
specialising in clinical research and Good Clinical Practice (GCP)
training and certification based in Guildford, UK, have entered into
a strategic partnership. Under the terms of the agreement, Argint
obtains exclusive distribution rights for the Academy’s training
courses throughout Central and South Eastern Europe (CEE/SEE).
|
 |
|
|
|
|
|
|
|
24.08.2010 Oxford
BioMedica plc: Interim Results for the Six Months
Ended 30 June 2010 |
|
Oxford Biomedica
(“Oxford BioMedica” or “the Company”) (LSE: OXB),
a leading gene therapy company, today announces its
unaudited interim results for the six months ended
30 June 2010. Year to date highlights include:
|
 |
|
|
|
|
|
|
|
20.08.2010 Putting the patient first: students work with elderly to
define the next stage of the connected health revolution |
|
Cambridge Consultants,
a leading technology
product design and development
firm, today shared
recommendations on how to
increase adoption of new
connected health technologies
that will help to improve
wellness among the nation's
growing elderly population. The
findings were based on field
research conducted by students
from the Tufts University School
of Engineering and individual
interviews with elderly patients
and their healthcare providers.
|
 |
|
|
|
|
|
|
|
18.08.2010 CEVEC Signs Global License Agreement for Human CAP-T
Technology with Life Technologies |
|
CEVEC Pharmaceuticals,
the
developer of a novel human
protein expression system
derived from amniocytes,
announced today the signing of a
co-exclusive worldwide licensing
agreement with Life Technologies
Corporation, a leading provider
of innovative life science
solutions based in Carlsbad,
California. Under the terms of
the agreement, Life Technologies
and CEVEC will co-operate to
offer optimized expression kits
based on CEVEC’s proprietary
CAP-T cells to the global life
science research community. Life
Technologies will pay CEVEC a
signing fee and various
milestone payments and royalties
on sales of the future products.
Further details of the agreement
were not disclosed. CEVEC will
continue to expand its global
license business of the CAP® and
CAP-T® technologies for
commercial use and industrial
development purposes.
|
 |
|
|
|
|
|
|
|
18.08.2010 Oxford BioMedica Announces
Licensing Agreement with Emergent BioSolutions Inc.
|
|
Oxford
Biomedica
(“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today
announces that it has signed a licensing
agreement with Emergent Product Development
Germany GmbH (“Emergent”), a wholly-owned
subsidiary of Emergent BioSolutions Inc. The
agreement grants Emergent non-exclusive rights
to Oxford BioMedica’s Hi-8®
PrimeBoost technology patents and a sub-licence
under poxvirus patents licensed to the Company
for the development and
commercialisation
of vaccines and therapeutics targeting eight
infectious diseases, including Tuberculosis.
|
|
|
|
|
|
|
|
|
16.08.2010 New Isolera™ UV-VIS Flash
Purification System Delivers Widest Wavelength Range Available to
Chemists |
|
Biotage
(STO: BIOT),
a leading developer of tools and technology for medicinal and
analytical chemistry, announces the introduction of the Isolera™
UV-VIS flash purification system. The UV-VIS system enables
detection of organic molecules with spectral absorbance between 200
nm and 800 nm making it the broadest wavelength detection flash
system available to chemists. The system provides detection capable
to near IR range. Applications for the UV-VIS system include natural
products (carotenoids, flavanoids, proanthocyanidins, etc.),
synthetic dyes, diagnostic dyes, and OLED chemicals.
|
 |
|
|
|
|
|
|
|
13.08.2010 Axis-Shield Welcomes
Formal Approval of Anti-CCP Antibody Testing for Diagnosis of Early
Rheumatoid Arthritis |
|
Axis-Shield
(LSE:ASD, OSE:ASD),
the
international in vitro diagnostics company, today welcomes the
publication of new classification criteria for rheumatoid arthritis
(RA) in the September 2010 edition of “Arthritis and Rheumatism”
Vol. 62, No. 9, pp 2569– 2581, by Aletaha et al. The revised
criteria have been approved by the American College of Rheumatology
(ACR) Board of Directors and the European League Against Rheumatism
(EULAR) Executive Committee, signifying that the criteria set has
been quantitatively validated using patient data, and it has
undergone validation based on an external data set.
|
 |
|
|
|
  |
|
|
10.08.2010 Anavex Appoints Contract
Research Organizations to Initiate Phase I/IIa Clinical Programs,
Regulatory Strategies in Alzheimer’s Disease |
|
Anavex Life Sciences Corp.
("ANAVEX") (OTCBB: AVXL)
today announced that it has signed a definitive master services
agreement with Genesis BioPharma Group (“Genesis”) and
ABX-CRO
Advanced Pharmaceutical Services (“ABX-CRO”)
to begin clinical studies and regulatory filings for ANAVEX 2-73,
its lead compound for the treatment of Alzheimer’s Disease.
|
 |
|
|
|
|
|
|
|
09.08.2010 Myconostica Announces CE
Marking of MycAssay™ Product Family on Additional Platforms |
|
Myconostica Ltd,
the UK-based medical diagnostic company developing and
commercialising rapid and highly specific tests for life-threatening
fungal infections, today announces the CE marking of its lead
products
MycAssay™ Aspergillus and MycAssay™
Pneumocystis on the Roche Lightcycler® 2.0 and Stratagene Mx3000
series platforms.
|
 |
|
|
|
|
|
|
|
05.08.2010 MediGene AG Reports Financial
Results for First Six Months of 2010: Continuing
Increase in Total Revenue, Significant Reduction of
Loss |
|
In the first six
months of 2010, the biotech company
MediGene AG
(Frankfurt, Prime Standard, TecDAX)
increased total
revenue by 26% to EUR 25.2 million, and
reduced the loss on an EBITDA basis by
20% to EUR -5.4 million. The net loss
was reduced by 60% to EUR -3.3 million.
These results are reported in compliance
with IFRS (International
Financial Reporting Standards).
|
 |
|
|
|
 |
|
|
06.08.2010 TEMPO study further demonstrates
the benefits of Azilect® in early Parkinson's
disease patients |
|
H.Lundbeck
A/S
and
Teva
Pharmaceutical Industries Ltd.
(NASDAQ:
TEVA) today announced newly published
long-term data on Azilect® (rasagiline
tablets) from the TEMPO study and its
open-label extension. The findings confirm
the long-term efficacy, safety and
tolerability of Azilect® in patients with
Parkinson's disease (PD) and further
demonstrate the benefits obtained with early
treatment initiation. The data was published
in the June 2010 issue of the International
Journal of Neuroscience.
|
 |
|
|
|
|
|
|
|
04.08.2010 Glycotope Received Regulatory Approval for Glycooptimized
and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First
Patients in Clinical Trial |
|
Glycotope
GmbH, a leading glycobiology company,
has received regulatory approval by
German and Italian regulatory
authorities for a Phase I study of
Glycotope´s next generation antibody
CetuGEX™ (GT-MAB 5.2-GEX) for the
treatment of various solid cancers.
|
 |
|
|
|
|
|
|
|
02.08.2010 MorphoSys Announces
Clinical Milestone from Strategic Alliance |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
announced today that it will
receive a milestone payment from Novartis in connection with the
initiation of a phase 1 clinical trial of a HuCAL-derived, fully
human antibody in the therapeutic area of ophthalmology. Today's
news marks the entry of the third HuCAL-derived antibody into human
clinical trials in 2010, following the advancement of one program
each from the alliances with Novartis and Centocor Ortho Biotech
earlier this year.
|
 |
|
|
|
|
|
|
All rights reserved